Unicycive Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Unicycive Therapeutics generated cash of -$18,283,000, which is less than the previous year. Cash used in financing activities reached the amount of $27,541,000 last year. Net change in cash is therefore $9,246,000.
Cash Flow
| 2019 | -1.17M | 0 | 1.16M |
|---|---|---|---|
| 2020 | -1.45M | 0 | 1.44M |
| 2021 | -5.76M | -29K | 22.37M |
| 2022 | -15.65M | -2K | -471K |
| 2023 | -18.28M | -12K | 27.54M |
UNCY Cash Flow Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Cash at beginning of period | 455K | 16.57M | 0 | 15K | 25K |
Operating activities | |||||
Net income | -30.54M | -18.05M | -10.01M | -2.26M | -2.16M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||
Depreciation and amortization | 284K | 161K | 13K | 0 | 0 |
Stock-based compensation expense | 1.76M | 1.04M | 966K | 232K | 24K |
| Deferred income tax benefit | 1.76M | 1.04M | 966K | 232K | 24K |
| Changes in operating assets and liabilities: | |||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 1.27M | 1.26M | 1.24M | -68K | 308K |
Cash generated by operating activities | -18.28M | -15.65M | -5.76M | -1.45M | -1.17M |
Investing activities | |||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -12K | -2K | -29K | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -12K | -2K | -29K | 0 | 0 |
Financing activities | |||||
Common Stock Issued | 28.03M | 11K | 22.39M | 141K | 1.16M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -15K | -160K | 0 |
Cash used in financing activities | 27.54M | -471K | 22.37M | 1.44M | 1.16M |
Net Change In Cash | 9.24M | -16.12M | 16.57M | -15K | -10K |
Cash at end of period | 9.70M | 455K | 16.57M | 0 | 15K |
| Data source | Data source | Data source |